Thanks for posting. 

Stock rallied late and put in a hammer on the charts. More than average volume. Hopefully that is the tone going forward.

Amarin could turn cash flow positive, IF U.S. sales of Vascepa didn't keep dropping. No generics in Canada.

Hope we get some good news in 1st qtr on the two other readouts because as we may need it to stem the selling.  This is what sellers may be seizing upon:  Fast track, orphan status, etc., yet now they are saying FDA filing not until 4th qtr 2026.  Come on. Yeah waiting to line up publication of study and manufacturing.  

Company had some SEC filings today which apparently are explaining the dilution (which was announced in Dec) and I guess that is behind the drop today 

Guess I lived another day to learn something. Apparently there has been a bill in Congress (sitting of course) to raise the annual capital loss limit from $3,000 to $14,000 and to index it to inflation. Called the Capital Loss Inflation Fairness Act. It is unfortunately being sat on by the chairman of the Ways and Means Committee.

https://stocktwits.com/GDog877/message/600060575

In case this investment never proves to be what us long term holders hope for, it might help using those losses before we all die.

What a disastrous last 30 days for the stock price.  Haven't seen anything that is so negative to warrant this, but definitely discouraged with the action. 

What is going on here, stock price whipsawed from one day to the next. Doesn't seem like any rhyme or reason.

I hope so too. Too many times I have seen a team look like a juggernaut one week and then, seemingly, have given their uniforms to a scout team the next week.

Hope that the colder weather in Philly doesn't affect them either.

I didn't know or realize that the Nasdaq price deficiency is not lifted immediately after a RS:

https://news.bloomberglaw.com/us-law-week/nasdaq-delisting-threat-is-tricky-for-companies-trading-below-1

I guess that is why companies have to choose a large enough RS to make sure that when the stock price gets hammered after the RS that it doesn't fall back under a buck again.

Delisting for a public company could be quite negative, but I wonder if the ultimate goal is to sell Vascepa/Vazkepa to BP whether it matters.  Yesterday Eli Lilly paid 2.5 billion for Scorpion Therapeutics, which is a private company. 

Sure, but market is supposed to be forward looking and the anticipation is that Xphozah sales are going to drop off a cliff

Lilly buying Scorpion Therapeutics for 2.5 billion. Scorpion is a private company and not exchange listed:

https://www.statnews.com/2025/01/13/eli-lilly-scorpion-cancer/#:~:text=SAN%20FRANCISCO%20—%20Eli%20Lilly%20said,Indianapolis%20company%20broadens%20its%20pipeline.

Another strong day for the stock price today whilst the overall market wasn't the greatest. Company issued a PR this morning highlights strong sales and estimates for peak sales for the two drugs. But realistically did not address what sales for X will be now in 2025 other than to say that it is not covered by Medicare and they will evaluate patients to see if they can help financially if a script is written. Hard to know what is behind the strength of stock price of late.

There's no question that you right.  Look at that last Investors Day or whatever it was called. We were amazed and shocked that after all that build up the company had absooutely nothing new to say.  We were all speculating as to what they would reveal.  So I assume they finally realize they would look pretty silly and not do themselves any good by showing up at the conference at this time. 

Nuke, I know this seems weird, because has we have seen this information months ago, yet like you say a very recent publication date. (probably because it is in a different publication).
But just look at the Results. Bold is my emphasis:

Nuke that data is only what the participants had at the start of the study. 

It couldn't look much different to anyone. At this very moment, reimbursement decisions coming slowly, script uptake also coming slowly, US market stalled and dropping, court cases stretching into a timeline as far as the eye can see. BUT, that is right now. Not predicting it will, but if any of that changes (for the better) the market will have a bunch to catch up. We shall see, but after so many years in the stock I am not giving up at this point. Very little left to lose at this point.

And, at least this board, has been teasing us about this potential new formulation, which may (or may not) be our savior here in the U.S. I can't count on it until I hear from management about it. And, are they playing close to the vest for competitive business reasons? Hard to give them the benefit of the doubt since they seem to have clammed up about everything. Anyway at least they passed the SS Fairness Act.

I'm fine with a BP running such a trial. As a matter of fact, I think BP would have an easier time convincing the Germans to reimburse, with or without such a trial. Hard to see management accepting anything less than 1 billion, probably a little more.

But back to reality, there doesn't seem to be even the slightest stirrings of any rumors of any kind of BO here. Not even a decision by management to do a strategic review. My guess is they want to be in a much stronger position before seeking a sale.

Wow, Sage 5 year chart - stock down 92%. Amarin 5 yr chart - stock down 97%.

Their financials look worse than Amarin. Maybe there is hope yet. Thanks for the heads up.

JRoon, I notice you used the word hope. I wish I knew more about the formulation, what it will take to get it approved, and if it truly will protect itself from infringement. I worry that if its benefit vs IPE is that you need to take half the number of pills, then maybe a number of actors (patients, docs, insurers) will be willing to take double the amount of Generic IPE to accomplish the same thing. Now if it is entirely a different entity that wouldn't happen, BUT by the same token, it would need an NDA wouldn't it.

Anyway, hopefully the company soon clues us in to all the dynamics of this.

Yes, fully agree that their plans going forward will carry by far the most weight. Need to convince the market in Amarin's future prospects. Would be great if we got some positive news about France and script uptake in the rest of the EU.

Possible but who knows.  For me it is more important whether it is better than expected or worse than expected.  

Last couple of weeks the market has given a bit of sheet kicking to many overvalued high flyers, but our little Amarin appears during that time to have become a little safe haven. Be nice if we slowly but surely keep rising and with some good news from the EU streak across that $1 mark.

OT: Healthcare insurance company calls doc in mid- surgery trying to deny hospital stay:

https://www.yahoo.com/news/unitedhealthcare-calls-doctor-mid-surgery-201800124.html

Yep, no reason for the comparison since they don't even sell Vascepa. It is only there to try to increase sales of the Generic they carry.

Yep and what plays into this and enables this lack of knowledge and confusion is the fact that scripts do not have the indication written on them. 

Jroon, I agree with the sentiment of your post that I am responding to and not particularly with your last post.  My reasoning is this:

If you go to their website and use the Search function and search for Vascepa, what comes up is Generic IPE. They do NOT even sell Vascepa. So it can't be said that they are describing the different uses for the drug and then letting the patient decide.  They are inducing infringement, clear and simple. 

Totally egregious:

"When used alongside a statin, Vascepa has been shown to reduce ones risk of a cardiovacualr event such as a heart attack or stroke."


And they sell it as Generic VASCEPA

Thanks JRoon. I had thought of what you said"

And, boy, wouldn't that truly fit the definition of scheming to infringe. On the part of a PBM.

I hate repeatedly bringing up this thing with CVS Caremark as I makes me appear a dunce, but I don't quite understand the idea that CVS signed some exclusive contract with Hikma (or pick any other mfr), and that bounced Vascepa off the formulary, for two reasons.

First, Vascepa was in the category of brand. They could bring it whatever Generics and still cover brand.

The second thing, is that I have Fed BCBS with CVS Caremark as the PBM. I have received a variety of GVs, the latest being Strides Pharma. Three different GVs and that is only since the July drop of Vascepa. So from my experience it is not as though CVS Caremark is only covering one GV in their formulary.

Now is it possible Caremark said "hey you guys have to match this price to be covered"? No idea, but doesn't the pharmacy also play some role as to what brands of the various drugs they carry? I don't see where my formulary says "this brand of Generic covered and another not"..

Would normally think PharmacyDude if he still followed here would know a more precise answer, but he is also in Canada, where I don't believe there are PBMs, or at least not in the form they are here.

Thanks Kiwi.  I know that the CEO has mentioned selling off or partnering RZ402 (DME) drug, but do you think his intentions would be to sell the entire company?

Yep as it is now I would not spend anything for marketing in the US.  

And I totally with your point JRoon.  My point is that absent all that marketing many docs aren't doingvtheir DD vis-a-vis their patients.  If the stuff is marketed to them they gravitate to it, otherwise no effort on their part to educate themselves and do best for their patients.  If they are aware of trials (like Strength - Kiwi's point) and hence are prescribing less mixed omega-3s, then they should be aware of R-I. 

Rezolute (Nasdaq: RZLT), a late-stage biopharmaceutical company, announced that the FDA granted Breakthrough Therapy Designation to ersodetug (RZ358) for treating hypoglycemia due to congenital hyperinsulinism (HI). This designation, aimed at expediting the development of treatments for serious conditions, is based on Phase 2b (RIZE) study results showing significant hypoglycemia improvement of 75% or better without clinically significant hyperglycemia.

CEO Nevan Charles Elam highlighted 2024 as a transformative year with key clinical milestones. The company plans to finish recruitment for the sunRIZE study and announce topline results in the second half of the year. Additionally, Phase 3 study for tumor HI is set to commence.

Key highlights from 2024:

FDA lifted partial clinical holds on the Phase 3 sunRIZE study, enabling U.S. site inclusion.
Received Innovation Passport Designation from the U.K. for congenital HI treatment.
Preclinical validation for treating hypoglycemia due to non-islet cell tumors (NICTs).
FDA clearance for a Phase 3 study for tumor HI, with topline results expected in 2026.
Received Orphan Drug Designation for tumor HI.
Raised $73 million in June to support clinical programs and operational goals into Q2 2026.

Well, maybe not NVDA, but there are a bunch of other tech stocks losing money with sky high valuations. We all are familiar with the idea that the market can stay irrational longer than we can stay solvent.

As far as docs, you can't have it both ways. JRoon says the docs need to be educated (Amarin's marketing was cut short) but yet you say ( or maybe it is AI saying that) that the docs have eschewed mixed omega-3s since they are aware of trials like STRENGTH. Well if they are aware of STRENGTH then they should be aware of Reduce-It, Jelis, Evaporate, Cherry, etc., yet I don't see a huge increase in scripts for Vascepa.

Thanks for posting Sleven.  All fine and dandy protecting the Generics with their skinny label but there is consideration or provision that the Generics infringe on indications outside that label, which to me seems like the bigger problem.  

Funny how most stocks today can't hold their morning gains.  Is all the money being sucked up by overpriced tech stocks?

All the defence of doctors is fine but doesn't explain when many just recommend their patients take OTC fish oil pills.  And believe it or not that is very prevalent.  

So many doctors are clueless.  Thinking about that, I guess that's DTC advertising in pharma works so well here in the States.  

I once saw an expose that showed that most advances in medicine take 11 years on average to get down to the practicing physician.  Heck it has been 6 years since R-I and these guys still blabbing about trigs.